Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

NCT04869137 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Merkel Cell Carcinoma
Neuroendocrine Carcinoma of the Skin
Trabecular Carcinoma of the Skin

Interventions

DRUG: Lenvatinib Oral Product
DRUG: Pembrolizumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]